Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL52414 | 1.00 | CTSK (0.33) | CTSKHDAC6CA1CA2CA7 | |
| SCHEMBL5657578 | 0.83 | CTSK (0.34) | CTSKHDAC6AAK1HDAC1HDAC2 | |
| SCHEMBL23279584 | 0.83 | CTSK (0.31) | CTSK | |
| SCHEMBL5657583 | 0.83 | CTSK (0.34) | CTSKHDAC6AAK1HDAC1HDAC2 | |
| SCHEMBL13489790 | 0.82 | AAK1 (0.30) | HDAC6CA1CA2CA7AAK1 | |
| SCHEMBL5559416 | 0.81 | CTSK (0.34) | CTSKHDAC6CA1CA2CA7 | |
| SCHEMBL4299159 | 0.81 | CTSK (0.34) | CTSKHDAC6CA1CA2CA7 | |
| SCHEMBL8274243 | 0.81 | CTSK (0.34) | CTSKHDAC6CA1CA2CA7 | |
| SCHEMBL14567869 | 0.80 | — | — | |
| SCHEMBL57627 | 0.80 | TUBB1 (0.33) | AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2374454-B1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI R&D MAN CO LTD (JP) | 2016-05-11 | — | — | EP | disclosed |
| US-20140309174-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO., LTD (JP) | 2014-10-16 | — | — | US | disclosed |
| US-20140309174-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO., LTD (JP) | 2014-10-16 | — | — | US | disclosed |
| US-20140309174-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO., LTD (JP) | 2014-10-16 | — | — | US | disclosed |
| US-8633224-B2 | Hemiasterlin derivatives and uses thereof in the treatment of cancer | EISAI CO., LTD. (JP) | 2014-01-21 | — | — | US | disclosed |
| US-8633224-B2 | Hemiasterlin derivatives and uses thereof in the treatment of cancer | EISAI CO., LTD. (JP) | 2014-01-21 | — | — | US | disclosed |
| US-8633224-B2 | Hemiasterlin derivatives and uses thereof in the treatment of cancer | EISAI CO., LTD. (JP) | 2014-01-21 | — | — | US | disclosed |
| US-20120309938-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO., LTD. (JP) | 2012-12-06 | — | — | US | disclosed |
| US-20120309938-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO., LTD. (JP) | 2012-12-06 | — | — | US | disclosed |
| US-8129407-B2 | Hemiasterlin derivatives and uses thereof in the treatment of cancer | EISAI INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-7064211-B2 | Hemiasterlin derivatives and uses thereof | EISAI CO., LTD. (JP) | 2006-06-20 | — | — | US | disclosed |
| WO-2005118525-A1 | SYNTHESIS OF AMINO-ALKOXY-HEPTANOIC ALKYL ESTER | F.HOFFMANN-LA ROCHE AG (CH) | 2005-12-15 | — | — | WO | disclosed |
| US-20050272665-A1 | Synthesis of alpha-amino-beta-alkoxy-carboxylic acid esters | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-08 | — | — | US | disclosed |
| US-20050239870-A1 | Prevention of restenosis of blood vessels after trauma, angioplasty or stenting; aminoalkylamide, piperidine-, indole-, or pyrrole-amide derivatives; anticarcinogenic agents | Eisai Co., Ltd., (JP) | 2005-10-27 | — | — | US | disclosed |
| US-20050171014-A1 | Conjugates of ligand linker and cytotoxic agent and related composition and methods of use | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH (US) | 2005-08-04 | — | — | US | disclosed |
| EP-1490054-A2 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | Eisai Co., Ltd (JP) | 2004-12-29 | — | — | EP | disclosed |
| US-20040229819-A1 | Hemiasterlin derivatives and uses thereof | EISAI CO., LTD. (JP) | 2004-11-18 | — | — | US | disclosed |
| US-20040121965-A1 | Method of treating resistant tumors | WYETH HOLDINGS CORPORATION (US) | 2004-06-24 | — | — | US | disclosed |
| WO-2004026293-A2 | HEMIASTERLIN DERIVATIVES FOR TREATING RESISTANT TUMORS | WYETH HOLDINGS CORPORATION (US) | 2004-04-01 | — | — | WO | disclosed |
| WO-2003082268-A2 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO. LTD (JP) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239870-A1 | Prevention of restenosis of blood vessels after trauma, angioplasty or stenting; aminoalkylamide, piperidine-, indole-, or pyrrole-amide derivatives; anticarcinogenic agents | EDNRA, ARG1, EDNRB | CTSK 1022/4885HDAC6 1344/4885CA1 3638/4885 |
| US-20120309938-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | DHCR7, HSD17B7, HCCS | CTSK 1987/4885HDAC6 1779/4885CA1 4689/4885 |
| US-20040121965-A1 | Method of treating resistant tumors | SLC11A2, VHL, REN | CTSK 964/4885HDAC6 227/4885CA1 121/4885 |
| US-20140309174-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | DHCR7, HSD17B7, HCCS | CTSK 1987/4885HDAC6 1779/4885CA1 4689/4885 |
| US-20040229819-A1 | Hemiasterlin derivatives and uses thereof | HSD17B7, CYP17A1, DHCR7 | CTSK 2268/4885HDAC6 1359/4885CA1 4663/4885 |
| US-20050171014-A1 | Conjugates of ligand linker and cytotoxic agent and related composition and methods of use | VCL, SELPLG, L3MBTL1 | CTSK 1932/4885HDAC6 535/4885CA1 292/4885 |
| US-20050272665-A1 | Synthesis of alpha-amino-beta-alkoxy-carboxylic acid esters | ALDH7A1, BCAT1, BCAT2 | CTSK 2415/4885HDAC6 4041/4885CA1 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.